Marilena Vrana: Securing Sustainable Plasma Supply for Europe’s Growing Patient Needs
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared a post on LinkedIn:
“I was glad to join with my PPTA colleagues Anita Brikman, James Knowles and Halide Tuna, the 2026 IPFA/EBA Symposium on Plasma Collection and Supply in Leuven this week.
The discussions focused on both progress and ongoing challenges in meeting plasma need for the growing patient need for plasma-derived medicines, including immunoglobulins and other life-saving and life-enabling therapies.
During the exchanges with peers, I emphasized that ‘self-sufficiency’ should be addressed through a multi-stakeholder dialogue that includes patients and physicians. It must be viewed through the lens of European strategic autonomy – not only national capacity and self-sufficiency – and grounded in actual patient need.
While patient need is still not comprehensively recorded across all Member States, data show that it continues to grow steadily in Europe and globally, driven by improved diagnostic technologies, new indications, and evolving disease detection strategies.
Ensuring patients’ long-term peace of mind requires that we align policy ambition with real-world demand.
There is a clear opportunity for more aligned strategies across stakeholders – from streamlining contract fractionation arrangements to strengthening resilient supply chains that better serve patients in Europe and beyond.
Stronger public-private partnerships, supported by data and best practices, will be critical to closing availability gaps and advancing our collective responsibility to secure long-term sustainability of supply.
I look forward to continuing the dialogue at PPC2026 in Milan – an important checkpoint for our community – where the private sector’s role in strengthening Europe’s Resilience, Reach and Responsibility in plasma and plasma derived medicines will be further discussed.
Together, we can continue moving faster and further in delivering for all patients.”
Find more posts featuring Marilena Vrana on Hemostasis Today.
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage
-
Oct 10, 2026, 02:17Dino Mehic: Managing Heavy Menstrual Bleeding in Patients with BDUC
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia